0000950170-24-075718.txt : 20240620
0000950170-24-075718.hdr.sgml : 20240620
20240620170043
ACCESSION NUMBER: 0000950170-24-075718
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240617
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Verwiel Frank
CENTRAL INDEX KEY: 0001545794
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 241057296
MAIL ADDRESS:
STREET 1: C/O INTERMUNE, INC.
STREET 2: 3280 BAYSHORE BLVD.
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-06-17
0001652130
Intellia Therapeutics, Inc.
NTLA
0001545794
Verwiel Frank
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
true
false
false
false
true
Common Stock
2024-06-17
4
S
false
1505
25.00
D
17948
D
The reported sale of 1,505 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 7, 2024.
/s/ James Basta, attorney-in-fact
2024-06-20